CytomX Therapeutics CTMX Contract Liabilities
Contract Liabilities at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about CytomX Therapeutics's contract liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CytomX Therapeutics's contract liabilities?
- CytomX Therapeutics (CTMX) reported contract liabilities of $979K in Q1 2026.
- How has CytomX Therapeutics's contract liabilities changed year-over-year?
- CytomX Therapeutics's contract liabilities decreased by 94.0% year-over-year, from $16.21M to $979K.
- What is the long-term trend for CytomX Therapeutics's contract liabilities?
- Over 5 years (2020 to 2025), CytomX Therapeutics's contract liabilities has grown at a -64.4% compound annual growth rate (CAGR), from $276.65M to $1.59M.
- What does contract liabilities mean?
- Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.